May 15, 2026 04:30PM
May 5, 2026 08:00AM
May 5, 2026 08:00AM
Apr 27, 2026 08:00AM
Apr 27, 2026 08:00AM
Apr 21, 2026 08:02AM
Apr 21, 2026 08:00AM Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Mar 31, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 6, 2026 08:01AM
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM
Feb 18, 2026 08:15AM Allarity doses first patients in VA-funded lung cancer trial
Feb 18, 2026 08:15AM
Feb 3, 2026 08:00AM
Feb 3, 2026 08:00AM
Dec 31, 2025 08:00AM
Nov 14, 2025 09:00AM
Sep 22, 2025 08:01AM
Sep 22, 2025 08:00AM Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
Aug 26, 2025 08:00AM
Aug 26, 2025 08:00AM
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM
May 9, 2025 04:05PM
Apr 25, 2025 08:01AM
Apr 25, 2025 08:00AM Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
Mar 31, 2025 04:05PM
Mar 13, 2025 08:33AM
Mar 13, 2025 08:30AM
Mar 6, 2025 08:00AM
Feb 24, 2025 08:00AM
Feb 6, 2025 08:01AM
Feb 6, 2025 08:00AM Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Jan 30, 2025 08:06AM
Jan 30, 2025 08:00AM
Nov 18, 2024 08:03AM
Nov 18, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 18, 2024 12:47PM
Jul 22, 2024 06:32AM Allarity Therapeutics (ALLR) Outlines Company’s 2024 Progress and Objectives
Jul 22, 2024 06:30AM
Jun 25, 2024 08:00AM
May 14, 2024 04:01PM
May 2, 2024 08:03AM
May 2, 2024 08:00AM
Dec 5, 2023 07:31AM
Dec 5, 2023 07:30AM Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Jul 5, 2023 09:46AM

322,308 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All